Byline: Rob Malone
Victoria “Vicky” Ann Michelis was a woman of fierce intellect, unyielding empathy, and a profound, intuitive sense of justice. To those who knew her, she was a champion for the underdog—a person who stood as a bulwark for the vulnerable and a sharp critic of the self-important. When she was diagnosed with a rare and aggressive form of ovarian cancer, she refused to let the disease define the narrative of her life. Today, her legacy persists not through the illness that claimed her, but through the tangible, forward-looking impact of the Victoria Ann Michelis Fund. By bridging the gap between patient advocacy and cutting-edge immunotherapy research, her fund is working to ensure that the "same old paths" of treatment are replaced by the innovative, life-saving breakthroughs of the future.
The Landscape of Ovarian Cancer: A Persistent Global Challenge
To understand the necessity of the work being supported by the Victoria Ann Michelis Fund, one must first confront the sobering reality of ovarian cancer. The ovaries, vital reproductive organs responsible for the production of eggs and hormones, can become the site of malignancy when cells begin to divide and grow uncontrollably. While once thought to originate primarily in the ovaries themselves, contemporary medical research has identified the fallopian tubes as a significant origin point for many of these cancers. Furthermore, the peritoneum—the lining of the abdominal cavity—can host closely related, equally devastating malignancies.
The statistics are a clarion call for urgent action. Ovarian cancer remains a leading cause of cancer-related mortality among women globally. In 2024 alone, approximately 331,000 women were diagnosed with the disease, with more than 200,000 losing their lives to it. In the United States, the burden remains heavy; projections for 2026 indicate 21,010 new cases and 12,450 deaths. These numbers represent more than just data points—they represent thousands of lives cut short, leaving families and friends to grapple with the profound void left in their wake.
Chronology: A Life of Tenacity and Advocacy
Vicky’s journey was defined by a consistent thread of empathy. Whether in her professional life or her personal interactions, she held a deep-seated disdain for the arrogant and a protective, nurturing instinct for the marginalized.
The Onset of Battle
The diagnosis of small cell carcinoma of the ovary, hypercalcemic type, arrived following symptoms of hypercalcemia—an excess of calcium in the bloodstream. This specific diagnosis is remarkably rare and notoriously aggressive. When confronted with this news, Vicky’s reaction was characteristically pragmatic. She did not retreat; she engaged. She transformed into a researcher, a self-advocate, and a navigator of the complex medical landscape.
“The researcher came out,” recalls her dear friend Rob Malone. “She investigated her options, sought out doctors, and became a determined advocate for herself.”
The Illusion of Remission
After years of intensive, grueling treatment—including multiple surgical interventions and rounds of chemotherapy—Vicky achieved a period of remission. It was a victory hard-won, and for a time, it felt as though she had beaten the odds. During this period, her focus shifted outward. Recognizing how difficult it is to diagnose ovarian cancer in its early stages—partly due to the vague, subtle symptoms that often mimic less serious conditions—she founded a nonprofit organization. Her goal was simple but vital: to educate others and help them recognize the warning signs of a disease that often hides in plain sight.
The Return and the Legacy
In 2017, the cancer returned. Despite her exhaustion and the physical toll of previous treatments, Vicky remained relentless in her pursuit of care. She sought out clinical trials and pushed for aggressive interventions, driven by a hope for more options. When she passed in 2020, she left behind a directive that would eventually transform her personal fight into a global endeavor. She entrusted her estate to Rob Malone with the express intent of creating a charitable foundation that would continue to support those who, like her, were fighting for their lives.
Supporting Innovation: The Victoria Ann Michelis Fund and the CRI
The Victoria Ann Michelis Fund was established to carry forward the values that defined Vicky: generosity, compassion, and a commitment to the underdog. The fund provides critical support to smaller, US-based nonprofits that address systemic issues such as homelessness, food insecurity, animal welfare, and—most significantly—cancer research.
Why the Cancer Research Institute (CRI)?
Rob Malone’s decision to align the fund with the Cancer Research Institute (CRI) was rooted in a shared vision of progress. “Vicky was frustrated that she kept being put down the same old chemotherapy paths for treatment,” Malone explains. “She felt there wasn’t something innovative or different being offered. I think the CRI appeals to her because they are actively pursuing the ‘other’ options—the breakthroughs that could change the trajectory of care.”
Advancing Immunotherapy
The fund currently supports the work of CRI Irvington Postdoctoral Fellow Dr. Hyung Jun Kim. Dr. Kim’s research is focused on a critical bottleneck in oncology: the manipulation of macrophages. Macrophages are immune cells that have the potential to destroy tumors, but in the environment of solid tumors—such as those found in ovarian cancer—they are often "reprogrammed" by the cancer to protect the tumor rather than attack it. By reengineering these cells to overcome the suppressive environment of the tumor, Dr. Kim’s research aims to turn the body’s own immune system into a more effective weapon against advanced disease.
Structural Data: The Path Toward AI-Driven Discovery
Beyond specific fellowships, the Victoria Ann Michelis Fund has made a multiyear commitment to the CRI Discovery Engine. This initiative represents a paradigm shift in how oncological data is collected and utilized.
In the current medical landscape, research data is often siloed within individual institutions. The Discovery Engine aims to break these silos by generating standardized, high-quality, and AI-ready datasets. By enabling researchers across the globe to compare findings, identify patterns, and iterate upon each other’s work, the initiative seeks to accelerate the pace of discovery. Given that ovarian cancer is a primary focus area for the Discovery Engine, this investment is a direct strike against the status quo of treatment, aiming to bring new immunotherapy options to the clinic faster than ever before.
Implications: A Future Defined by Options
The legacy of Victoria Ann Michelis is a powerful testament to the impact one person can have on the future of medical science. By focusing on immunotherapy—a field that harnesses the immune system to recognize and eliminate cancer cells—the funding provided in her name is helping to move the needle away from the "standard of care" and toward a future of personalized, precision medicine.
The implications for patients are profound. For a disease that has historically been characterized by late-stage diagnosis and limited therapeutic variety, the move toward innovative immunotherapy offers more than just clinical data; it offers the potential for extended life and improved quality of time.
A Lasting Commitment
Vicky’s life was not defined by her illness, and her death did not mark the end of her influence. Through the Victoria Ann Michelis Fund, her commitment to the "underdog" now manifests in the support of scientists who are challenging the most formidable obstacles in medicine.
For families currently walking the path that Vicky walked, the work of the fund offers a beacon of hope. It ensures that the frustrations she faced—the lack of innovative options and the reliance on outdated chemotherapy paths—are addressed with vigor and urgency. As the Victoria Ann Michelis Fund continues to collaborate with organizations like the CRI, it serves as a bridge between the lessons of the past and the breakthroughs of the future.
Vicky wanted to be remembered for how she lived: with courage, with heart, and with an unwavering belief in the potential for change. Today, that legacy is firmly etched into the fabric of modern oncology, providing a path toward a world where more people facing ovarian cancer have the resources, the time, and the treatment options they so desperately deserve.
To learn more about how you can support this critical research and join the effort to create more time for those fighting cancer, visit the Cancer Research Institute or explore the work of the Victoria Ann Michelis Fund.
